fig3
Figure 3. Cellular immunotherapy for MPM. MPM: Malignant pleural mesothelioma; CAR-T: chimeric antigen receptor T cells; PD1: programmed cell death protein 1; NAC-T: nanobody-armored CAR-T cells; TRuC-T: T-cell receptor fusion construct; FAP: fibroblast activation protein; LET-SeNPs: lentinan-functionalized selenium nanoparticles; NK: natural killer.
